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http://dxAbstract: There is increasing recognition that many if not most common chronic pain conditions are
heterogeneous with a high degree of overlap or coprevalence of other common pain conditions along
with influences from biopsychosocial factors. At present, very little attention is given to the high de-
gree of overlap of many common pain conditions when recruiting for clinical trials. As such, many if
not most patients enrolled into clinical studies are not representative of most chronic pain patients.
The failure to account for the heterogeneous and overlapping nature of most common pain conditions
may result in treatment responses of small effect size when these treatments are administered to pa-
tients with chronic overlapping pain conditions (COPCs) represented in the general population. In this
brief review we describe the concept of COPCs and the putative mechanisms underlying COPCs.
Finally, we present a series of recommendations that will advance our understanding of COPCs.
Perspective: This brief review describes the concept of COPCs. A mechanism-based heuristic model
is presented and current knowledge and evidence for COPCs are presented. Finally, a set of recom-
mendations is provided to advance our understanding of COPCs.
ª 2016 by the American Pain Society
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.doi.org/10.1016/j.jpain.2016.06.002that some common or highly prevalent chronic pain con-
ditions appear to coexist, and these coexisting conditions
appear to be more prevalent in women compared with
men. The concept of coexisting pain conditions has
been recognized by the National Institutes of Health
and the US Congress as a set of disorders that coaggre-
gate and include, but should not be limited to, temporo-
mandibular disorder (TMD), fibromyalgia (FM), irritable
bowel syndrome (IBS), vulvodynia, myalgic encephalo-
myelitis/chronic fatigue syndrome, interstitial cystitis/
painful bladder syndrome, endometriosis, chronic
tension-type headache, migraine headache, and chronic
lower back pain. Collectively, these conditions are
increasingly referred to as chronic overlapping pain con-
ditions (COPCs).115
Recently, Analgesic, Anesthetic, and Addiction Clinical
Trial Translations, Innovations, Opportunities, and Net-
works (ACTTION) and the American Pain Society (APS)
proposed a framework for classification of chronic pain
conditions, known as the ACTTION-APS Pain Taxonomy
(AAPT).33 AAPT working groups are currently applyingT93
T94 The Journal of Pain COPCsthe taxonomy by developing diagnostic criteria for most
common chronic pain conditions, including those listed
previously that often coexist as COPCs. Although the
AAPT criteria will be specific to individual pain condi-
tions, clinicians and investigators will also need to
consider COPCs in their application of AAPT for classifica-
tion of patients. This brief overview will discuss epidemi-
ological approaches and principles that help
conceptualize and define COPCs, and we will describe
putative etiological processes that underlie clinical
manifestations of COPCs. Also, we will consider the
implications of COPCs for the development and imple-
mentation of the AAPT taxonomy.Table 1. Current Approaches to Classifying/
Diagnosing Each COPC
CONDITION APPROACH
Fibromyalgia ACR 1990129
ACR 2010128
Survey Criteria127
Irritable bowel syndrome ROME III26
TMD TMD Screener38
DC/TMD 201492
ME/CFS CDC 1994 (CFS)35
Revised Canadian 2010 (ME/CFS)53
IOM 2015 (SEID)18
Tension headache ICHD III47
Migraine headache ICHD III47
Chronic low back pain NIH Task Force20
Endometriosis Epidemiology case definition52
IC/PBS NIDDK54
Vulvodynia Screening46,86
Consensus statement due out 2015
Abbreviations: COPC, chronic overlapping pain condition; ACR, American Col-
lege of Rheumatology; ROME III, ROME III irritable bowel syndrome diagnostic
guidelines; TMD, temporomandibular disorders; DC, diagnostic criteria for
temporomandibular disorders; ME, myalgic encephalomyelitis; CFS, chronic fa-
tigue syndrome; CDC, Centers for Disease Control and Prevention; IOM, Insti-
tute of Medicine; SEID, systemic exertion intolerance disease; ICHD,
International Classification of Headache Disorders; NIH, National Institutes of
Health; IC/PBS, interstitial cystitis/painful bladder syndrome; NIDDK, National
Institute of Diabetes and Digestive and Kidney Diseases.Epidemiology of COPCs
Epidemiology is concerned with the distribution and
determinants of illness in human populations. All 4 key
words in this definition merit critical appraisal in the
context of COPCs.
The distribution of illness is measured most commonly
as prevalence and incidence. Prevalence represents the
proportion of people in a defined population who have
the illness at a defined time. Conceptually simple, preva-
lence is typically measured using cross-sectional studies.
Aggregated across such studies, the prevalence of individ-
ual COPCs ranges from 4 million (myalgic encephalomy-
elitis/chronic fatigue syndrome) to 44 million (IBS).115
Incidence is the rate at which illness develops in a
population, making it more challenging to measure
than prevalence in part because of the requirement for
a longitudinal design and needing to deal with illnesses
that can remit, recur, or alter in severity—hallmarks of
most COPCs. For example, the Orofacial Pain: Prospective
Evaluation and Risk Assessment (OPPERA) prospective
cohort study investigated onset of painful TMD in US
adults who had no previous experience of the condition
when enrolled. Symptoms of the condition were evalu-
ated prospectively, once every quarter. During a median
3-year follow-up period, one-third of study participants
developed symptoms in at least one of the quarters, and
approximately one-third of those individuals experienced
recurrence.98 Overall, 1 in 10 developed examiner-verified
painful TMD.95
Determinants refer to the causes of illness in a popula-
tion. Concepts of causation are inherently more compli-
cated than descriptions of the distribution of illness. In
principle, the best evidence of causation would come
from an experimental study design in which people are
assigned at random to be exposed or not exposed to a
putative cause. Although such a design would be
feasible for something that prevents disease, it would
not be ethically acceptable to expose people to a
putative risk of a disease. Instead, we must rely on rigor-
ously designed observational studies.49 In the case of
COPCs, many are defined as being ‘‘idiopathic,’’ as not
being able to be explained by injury or pathology in
the tissues from which the pain originates, or both.23
For COPCs, aspects of the biopsychosocial model have
been proposed to account for their occurrence.17,123Another fundamental problem arises in defining the
illness itself. The very starting point for any epidemio-
logic study is a ‘‘case definition’’ of the illness under
study, so that those with the illness can be counted sys-
tematically when determining, say, prevalence in a pop-
ulation. For many individual COPCs, the task of case
definition has been aided considerably in recent decades
thanks to consensus-derived, evidence-based case classi-
fications (Table 1). However, there are no such case clas-
sifications for COPCs as a whole nor is there unanimity
regarding the causes of overlap. This problem is not
unique to pain research. For example, one systematic re-
view of evidence for overlap of unexplained clinical con-
ditions reported that many instances of overlap were
simply due to applying the same criteria (eg, ‘‘fatigue’’)
to 2 or more clinically distinct syndromes.1 These authors
concluded ‘‘The diagnosis assigned to patients with .
these [unexplained] illnesses depends more on the chief
symptom and clinician specialty than the actual illness.’’
In principle, the problem can be circumvented in epide-
miologic studies when all selected COPCs are evaluated
independently, on the basis of accepted criteria for
each condition. The latter, however, begs the question
as to which COPCs should be evaluated. If the goal is to
determine comorbidity, defined as ‘‘any distinct addi-
tional entity that has existed or may occur during the
clinical course of a patient who has the index disease un-
der study,’’31 then the list could extend well beyond con-
ditions that are primarily painful to include physical
diagnoses such as hypertension, mental health condi-
tions such as depression, or aspects of social health. For
Maixner et al The Journal of Pain T95simplicity, we start with the 10 diagnostic entities listed
earlier but empirical investigation may expand this list
over time.
The population under study is a critical component of
any epidemiologic study, but the apparent simplicity of
the concept can be misleading. A 1946 study10 of over-
lapping health conditions provided a classic illustration
of bias that can be created when making inferences
about etiology in the population at large using data
from a study of a different population. In the study, Berk-
son used basic principles of probability to investigate an
apparent relationship between cholecystic disease and
risk of diabetes mellitus that had been documented in
studies of hospital patients. At the time, gall bladders
were being removed because cholecystic disease was a
suspected cause of diabetes in the population at large
because it was seen frequently in patients with diabetes.
Berkson showed that the statistical association observed
in hospital patients was spurious because of selection
bias in which multiple diagnoses are more common in
the hospital than in the general population.10 The lesson
is relevant 7 decades later; if wewant to learn about etio-
logic contributions underlying COPCs in the population,
it is critical to conduct epidemiologic studies in samples
selected at random from the population, not from hospi-
tal patients.
The remaining parts of this section report findings
from our analysis of publicly available data from the Na-
tional Health Interview Survey (NHIS). The survey, con-
ducted annually by the National Center for Health
Statistics, selects a nationally representative sample of
the civilian, noninstitutionalized population of the
United States. The survey uses a multistage, stratified,
clustered sampling design that covers the 50 statesFigure 1. Questions about pain asked in thand the District of Columbia, selecting approximately
40,000 households. Interviews are conducted with
approximately 100,000 people, with oversampling of
African American, Hispanic, Asian, and elderly minor-
ities. The face-to-face, computer-assisted personal inter-
views take approximately 1 hour and are conducted by
trained interviewers from the US Census Bureau. The
survey participation rate has exceeded 85% in recent
decades.
For the current report, we analyzed the NHIS data set
from the 2009 survey, restricting the analysis to people
aged 18 years or older. Case definitions were therefore
on the basis of a positive response to each of the self-
reported questions about pain in the back, head, neck,
or jaw/face (Fig 1). Case classification of joint pain was
on the basis of self-reported pain at 2 or more nonaxial
joints. Jaw or face pain was selected as the ‘‘index’’
pain condition, and the goal was to analyze its extent
of overlap with the other pain symptoms. This is consis-
tent with the concept of comorbidity which, by necessity,
begins with selection of an index condition.31 Although
this is a useful way to illustrate features of overlapping
pain in the US population in this article, it should be
noted that the choice of an index condition varies ac-
cording to the research question and the health care
setting, and hence is not self-evident.113 Five percent of
US adults reported jaw or face pain in the preceding
3 months, representing 11.5 million adults (Table 2).
Neck pain and severe headache or migraine each
had prevalence of approximately 15%, whereas back
pain was the most common of the pain conditions,
with prevalence of 28.5%.
Jaw/face pain overlapped considerably with headache
and neck pain (Fig 2). People with 1 of those conditionse 2009 National Health Interview Survey.
Table 2. Prevalence of 5 Self-Reported Pain
Symptoms, US Adults, 2009
SYMPTOM PEOPLE, %
PEOPLE
(MILLIONS), N
During past 3 mo
Back pain 28.5 64.8
Severe headache/migraine 15.8 36.0
Neck pain 15.4 35.0
Jaw/face pain 5.1 11.5
During past 30 d
$2 Nonaxial joints aching/painful 23.4 53.2
T96 The Journal of Pain COPCshad approximately twice the expected prevalence of
jaw/face pain, whereas people with both of them had
5.6 times the expected prevalence of jaw/face pain.
There was weaker overlap between jaw/face pain and
each of back pain and nonaxial joint pain, although co-
occurrence of the 2 types of body pain was associated
with threefold greater prevalence of TMD than
expected.
There was also considerable similarity in the sociode-
mographic distribution of jaw/face pain, headache, and
neck pain (Fig 3). Each peaked in prevalence at approxi-
mately the fifth decade of life, and was more frequent in
women compared with men. The prevalence of each was
greatest in Native American and least in Asian individ-
uals, although differences between Hispanic and non-
Hispanic individuals were small. Each exhibited large,
inverse associations between income and prevalence. In
contrast, back pain prevalence increased with age, was
only marginally greater in women compared with men,
and there was a less pronounced income gradient in its
prevalence.
Another way to quantify the overlap is to count the
number of pain conditions reported by each person
(Table 3). Of the estimated 21.9 million US adults who re-
ported 3 or more of headache, neck pain, back pain, or
nonaxial joint pain, 23.4% also reported jaw/face pain.
That represents 26.5 times the odds of jaw pain relative
to people who reported none of the other pain condi-
tions. Although less pronounced, there was also overlap3.1 M
2.5 M
2.4x
2.1 M
1.8x
3.8 M
5.6x
Jaw/face
pain
Headache
Neck pain
Figure 2. Venn diagram depicting overlap of jaw/face pain and oth
ysis of the 2009 National Health Interview Survey.of jaw pain andmedical conditions that are not primarily
painful (Table 4). Adults who reported 3 or more of 12
health conditions had 4.9 times the odds of jaw/face
pain relative to adults who reported none of those
health conditions.
When interpreting these findings, it is important to
note limitations that are inherent in self-reported symp-
toms collected in population-based surveys. Conversely,
the population-based sampling rigor of the NHIS pre-
cludes the possibility of selection biases, such as Berkso-
nian bias, as an explanation for the overlap observed in
our analysis. And although this analysis arbitrarily focused
on jaw and face pain as the ‘‘index’’ condition, the degree
of overlap is consistent with findings from a systematic
review of overlap in unexplained clinical conditions.1
There are 3 main implications from this brief investiga-
tion of pain symptoms in the US population. First, using
jaw pain as the ‘‘index’’ pain symptom, there was consid-
erable overlap with 4 selected sets of pain symptoms.
Although the overlap was most pronounced for other
pain experienced above the shoulders (headache, neck
pain), there was significant overlap with symptoms in
the back and in nonaxial joints. As discussed in the
Etiology andMechanisms section, this degree of anatom-
ical dispersion of symptoms is consistent with predomi-
nant models that explain overlap as a consequence of
disruption of central pain regulatory systems. Second,
sociodemographic patterns of variation in pain symptom
prevalence were strikingly similar for jaw pain, head-
ache, and neck pain, although not for back pain. Conven-
tionally, those sociodemographic characteristics are not
regarded as etiologic mechanisms responsible for over-
lap, which raises the intriguing question as to whether
searches for such mechanisms should statistically adjust
for background sociodemographic characteristics (eg,
through age standardization). Third, there was some
degree of overlap between jaw pain symptoms and
self-reported medical conditions that are not primarily
painful. This is consistent with the intriguing concept
that overlapping pain conditions and underlying disrup-
tion of central pain regulatory systems are responses that
are harnessed to combat pathology.422.8 M
1.4 M
1.1x
2.7 M
1.4x
4.6 M
3.3x
Jaw/face
pain
Low back
pain
2 or more
painful joints
er painful conditions, US adults, 2009. Source: the authors’ anal-
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Figure 3. Sociodemographic distribution of 4 pain conditions in US adults, 2009. Source: the authors’ analysis of the 2009 National
Health Interview Survey.
Maixner et al The Journal of Pain T97Etiology and Mechanisms
There are 2 defining features of COPCs: 1) their etiol-
ogies are multifactorial, and 2) the clinical manifesta-
tions of COPCs are diverse and present as a mosaic of
risk determinants for each COPC. Within each diagnostic
category, there appear to be clusters of patients who
appear to share characteristics with individuals in sub-
groupings of the other diagnostic categories (ie, COPCs).
We describe these characteristics (ie, putative multiple
causes) as a mosaic to emphasize our expectation thatno single risk determinate is necessary or sufficient to
cause 1 or more of the COPCs—just as multiple tiles are
needed to depict the image in a mosaic. Understanding
the interactions among multiple risk determinates, and/
or their grouping into clusters, is required to better
comprehend the etiological factors and mechanism(s)
that contribute to the development and maintenance
of COPCs.23
COPCs vary significantly in clinical presentation. In
addition to the cardinal symptomof pain, other common
Table 3. Association of Jaw/Face Pain and Other Pain Conditions, US Adults, 2009
NO. OF COMORBID
PAIN CONDITIONS*
POPULATION
(MILLIONS)
PEOPLE WITH JAW/FACE PAIN
ODDS RATIO 95% CLy
PEOPLE
(MILLIONS), N
PERCENTAGE OF
POPULATION
0 118.4 1.3 1.1% Referent
1 57.1 2.0 3.6% 3.2 2.6, 4.0
2 29.8 3.0 10.1% 9.8 7.7, 12.4
3 or 4 21.9 5.1 23.4% 26.5 21.2, 33.0
Total 227.2 11.5 5.1%
*1) Severe headache/migraine, 2) neck pain, 3) low back pain, and 4) 2 or more painful joints.
y95% Confidence limits for the odds ratio.
T98 The Journal of Pain COPCssymptoms include fatigue, sleep impairment, problems
with cognition, physical dysfunction, and disturbances
in affect (eg, anxiety, anger, depression). Importantly, it
is very likely that some groupings (ie, clusters) of patients
share more clinical signs and symptoms across pain con-
ditions than within a specific pain condition, consistent
with the view that some overlap in etiological mecha-
nisms underlies COPCs (Table 5).We and others have pro-
posed that multiple genetic factors, when coupled with
environmental exposures (eg, injury, infections, and
physical and psychological stress), increase the suscepti-
bility to highly prevalent COPCs by enhancing pain sensi-
tivity and/or affecting psychological vulnerability
(Fig 4).7,23
Each COPC likely has common and also unique path-
ways or mechanisms of pathology.23 Although themech-
anisms that underlie most of these conditions are still
poorly understood, COPCs have been associated with a
state of pain amplification resulting from either periph-
eral and/or central mechanisms manifested as wide-
spread hyperalgesia on the basis of quantitative
sensory testing, with sensory and also affective perturba-
tion9,12,41,72,107,117,134 (for review see Diatchenko et al23).
Importantly, there is substantial individual variability in
the relative contribution of pain amplification and psy-
chological phenotypes to COPCs.Pain Amplification and COPCs
A few studies have sought to prospectively identify
risk factors or risk determinants that are associatedTable 4. Association of Jaw/Face Pain and Health C
Adults, 2009
NO. OF MEDICAL
CONDITIONS*
POPULATION
(MILLIONS)
PEOPLE WITH
NO. OF PEOPLE
(MILLIONS)
0 102.0 2.8
1 60.4 2.8
2 34.7 2.3
3 or 4 30.1 3.6
Total 227.2 11.5
*Hypertension, heart disease, stroke, asthma, ulcer, cancer, diabetes, hay fever, sinu
y95% Confidence limits for the odds ratio.with or mediate the onset and maintenance of COPCs.
A well-established predictor of onset is the presence of
another chronic pain condition, which is characterized
by a state of pain amplification.118 Additionally, wide-
spread pain is a risk indicator for dysfunction associated
with painful TMD and for lack of response to treat-
ment.85 Several cross-sectional studies also suggest
that a substantial percentage of individuals with an es-
tablished COPC including TMD,68-71,91 IBS,58,117,120-122
FM,12,43,101,102 migraine headache,59,65,119 and
vulvodynia66,83 are characterized by a state of pain
amplification (for review see Yunus130-132). A review
on this topic by Yunus130 notes that a common feature
inherent in a large percentage of patients with COPCs
is enhanced pain sensitivity (Table 6). Whether pain
amplification represents a risk determinant versus a
consequence of COPCs remains a topic of debate. We
previously reported that individuals who are more sen-
sitive to noxious stimuli are significantly more likely to
develop painful TMD than those who are less sensitive
(risk ratio = 2.7).96 However, more recent findings from
a much larger cohort challenge this initial finding, and
on the whole there is little evidence that sensitivity to
experimental pain stimuli (thermal, mechanical, pres-
sure) predict the onset or susceptibility to TMD and
possibly other COPCs. However, it is clear that a state
of increased pain sensitivity is augmented when TMD
and perhaps other COPCs develop, suggesting that
pain amplificationmay instead play a role in themainte-
nance (ie, chronification) rather than the onset (suscep-
tibility) of COPCs.99 These findings suggest that painonditions That Are Not Primarily Painful, US
JAW/FACE PAIN
ODDS RATIO 95% CLy
PERCENTAGE OF
POPULATION
2.7% Referent
4.6% 1.7 1.4, 2.1
6.8% 2.6 2.1, 3.2
12.0% 4.9 4.1, 5.9
5.1%
sitis, chronic bronchitis, kidney disease, and liver disease.
Table 5. Published Estimates of Overlap
Between Index Conditions and Other COPCs
INDEX CASE
STATUS
COMORBIDITY (PERCENTAGE OVERLAP)
FM IBS TMD CFS VVD
FM 8037 7582 642 NA
IBS 41133 1657 1457 NA
TMD 24133 642 202 NA
CFS 55133 5837 4260 NA
VVD 23133 2575 2039 875
Abbreviations: COPC, chronic overlapping pain condition; FM, fibromyalgia; IBS,
irritable bowel syndrome; TMD, temporomandibular disorders; CFS, chronic fa-
tigue syndrome; VVD, vulvodynia; NA, not applicable.
Maixner et al The Journal of Pain T99amplification, and the associated processes that
mediate pain transmission and modulation, represent
key factors in maintaining COPCs.
Enhanced pain perception experienced by patients
with COPCs may result from a dysregulation in periph-
eral systems, central systems, or both, that produce dy-
namic, time-dependent changes in the excitability and
response characteristics of neuronal and glial cells,
which may contribute to the central sensitization
and the enhanced temporal summation (ie, wind-up)
of nociceptive input observed in patients with COPCs.
This dysregulation can also contribute to alteredFigure 4. This model depicts likely determinants that contribute to
ping pain conditions (COPCs). These factors are determined by gene
vidual’s psychological profile and pain amplification status. These 2
onset and persistence. Likely modifiers of the interaction between
Abbreviations:MAO,monoamine oxidase; GAD65, glutamate decarb
sive element binding protein 1; GR, glucocorticoid receptor; CACNA
POMC, proopiomelanocortin; NET, norepinephrine transporter; BDN
IKK, IkB kinase; COMT, catechol-O-methyl transferase.mood, motor, autonomic, and neuroendocrine re-
sponses as well as altered pain perception (Fig 4).7,23
However, it should be noted that not all patients
with an established COPC exhibit pain
amplification.41 For example, although most TMD pa-
tients show enhanced sensitivity to ischemic pain,69
approximately 25% of TMD patients show no change
in ischemic pain perception relative to control subjects
(Maixner and Fillingim, unpublished observation).
Additionally, in a sample of interstitial cystitis pa-
tients, 81% exhibited widespread pain beyond the
pelvic region (eg, suggestive of a more central and sys-
temic disturbance), whereas only 19% appeared to
have symptoms confined locally.77 These findings are
also observed for individuals presenting with chronic
TMD and97 strongly suggest that there are individual
variations in the factors that contribute to pain sensi-
tivity, which may create clusters of signs and symptoms
observed in COPCs.41,90,106,107,111,126 These findings
also suggest that there may be specific mechanisms
operating within certain individuals that transform a
localized pain condition into one that resembles a
COPC. Therefore, for optimal classification of COPCs,
it is important to characterize the heterogeneity
of clinically measurable signs and symptoms in
patients with COPCs, which will permit the patients
with COPCs to be assigned to specific clusters or
subgroups.the risk of onset and maintenance of common chronic overlap-
tic variability and environmental events that determine an indi-
primary domains are interactive and influence the risk of pain
genetic and environmental factors include sex and ethnicity.
oxylase; NMDA,N-Methyl-D-aspartic acid; CREB1, CAMP respon-
1, calcium channel, voltage-dependent, T type, alpha 1I subunit;
F, brain-derived neurotrophic factor; NGF, nerve growth factor;
Table 6. Number of Studies and Number of Patients Examined (Total N) Who Report an Increase in
Pain Sensitivity Across Nociceptive Modalities and Across COPCs
STIMULUS FM CFS IBS TTH Migraine TMD MPS/RSTPS PD
Pressure (somatic) 15 (580) 4 (178) 3 (117) 2 (42) 9 (462) 1 (20)
Pressure (rectal) 26 (822)
Heat (somatic) 12 (480) 2 (21) 1 (50) 3 (117) 3 (76) 3 (137) 2 (42)
Heat (rectal) 1 (46)
Cold (somatic) 8 (255) 1 (33) 1 (41) 2 (184)
Electric (cutaneous) 4 (61) 1 (12) 2 (36)
Electric (intramuscular) 2 (41) 1 (23) 2 (36) 1 (10)
Electric (spinal reflex) 2 (107) 1 (14) 1 (40) 1 (27)
Electric (rectal) 2 (21)
Ischemic 1 (60) 2 (72)
Hypertonic saline 2 (41) 1 (22) 1 (11)
Auditory stimulus 1 (20) 1 (15) 1 (65)
Abbreviations: COPC, chronic overlapping pain condition; FM, fibromyalgia syndrome; CFS, chronic fatigue syndrome; IBS, irritable bowel syndrome; TTH, tension type
headache; TMD, temporomandibular disorders; MPS, myofascial pain syndrome; RSTPS, regional soft tissue pain syndrome; PD, primary dysmenorrhea.
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Heightened psychosocial vulnerability represents
another domain of risk factors for COPCs (Fig 4). Many
patients with COPCs tend to have elevated depression,
anxiety,107,111,114 and perceived stress9 relative to pain-
free control subjects. A heightened burden of physical
symptoms across multiple somatic systems is associated
with more than a twofold increase in TMD incidence,
decreased improvement in TMD facial pain after
5 years,80 and increased pain after treatment.74 High
symptom burden has been associated with new onset
of several COPCs, including TMD, widespread pain,
and low back pain.4,45,64,72 Somatic symptom burden is
also associated with the progression from acute to
chronic TMD.36 Additional psychosocial risk factors for
development, persistence of COPCs, or both include
depression, anxiety, psychosocial stress, and passive
coping.55,64,76,96 These results suggest that multiple
psychosocial factors, including somatic symptom
burden, negative affect/mood, and environmental
stress, independently or jointly contribute to the risk
of onset and maintenance of COPCs and are therefore
incorporated into the AAPT (see Edwards et al28 and
Turk et al110 in this issue of The Journal of Pain). Howev-
er, like pain amplification, there are clusters of patients
with COPCs who manifest mosaics of psychological pro-
cesses and there will likely be large populations or clus-
ters of patients with COPCs who display common and
also unique psychological risk factors. There is a need
to examine the heterogeneity of shared and unique psy-
chological factors and clusters in large populations of
patients with COPCs.
Genetic Variations Influencing Pain
Amplification and Psychosocial
Vulnerability
In the Etiology and Mechanisms section, we proposed
that there are 2 major interactive domains that
contribute to the vulnerability of developing and main-
taining COPCs: pain amplification and psychosocial
vulnerability (Fig 4). Each of these domains is influencedby genetic variants that mediate the activity of physio-
logical pathways that underlie pain amplification and
cognitive and affective responses. Thus, individual poly-
morphic variations in genes coding for key proteins
that regulate these pathways interact with environ-
mental factors, such as physical or emotional stress, to
produce a phenotype that is vulnerable to the develop-
ment of COPCs. The commonality of pain amplification
and psychosocial vulnerability in many patients with
COPCs may shed light on common genetic processes
responsible for the symptoms that cut across COPCs in
otherwise anatomically localized pain conditions.
Clinical and experimental pain perception are influ-
enced by genetic variants.22,24 The relative importance
of genetic factors in human pain perception is
becoming clearer with reported heritability for pain
perception across several experimental modalities to
range from 22% to 60%.78,79 Several recent studies
have also established genetic associations with a
variety of psychological traits and disorders that
influence risk of developing COPCs. Twin studies show
that 30% to 50% of individual variability in the risk of
developing an anxiety disorder is due to genetic
factors.40 The heritability of unipolar depression is also
remarkable, with estimates ranging from 40% to
70%.62 Moreover, normal variations in these psycholog-
ical traits show substantial heritability.11,29,30,88 See
Supplementary Table 1 for a more comprehensive pre-
sentation of genetic variants that are associated with
pain sensitivity and COPC conditions.
Withadvances inhigh-throughputgenotypingmethods,
the number of genes associated with pain sensitivity
has increased rapidly. A few examples of the genes associ-
ated with this domain include adrenergic receptor b2,21
catechol-O-methyltransferase,24,25,135 dopamine receptor
D4,50 guanosine-5’-triphosphate cyclohydrolase 1,105
m-opioid receptor,34,93 and serotonin transporter.63 These
genes are prominent among those implicated as genetic
risk factors for complex psychological disorders such as
depression,21,32,87 anxiety,8,21 and stress response.5,6,116
Consistent with their role in pronociceptive traits, these
genes have also been associated with 1 or more COPCs
Maixner et al The Journal of Pain T101(see Supplementary Table 1 for a more comprehensive
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Because it is highly likely that COPCs share common
underlying pathophysiological mechanisms, it is ex-
pected that a set of functional genetic variants will be
associated with comorbid COPCs and related signs
and symptoms. For example, a common single-
nucleotide polymorphism in codon 158 (val158met) of
the catechol-O-methyltransferase gene is associated
with pain ratings, m-opioid system responses,84 TMD
risk,25 and FM development44 as well as addiction,
cognition, and common affective disorders.81 Common
polymorphisms in the promoter of the serotonin trans-
porter gene are associated with depression, stress-
related suicidality,15 anxiety,40 somatization, and TMD
risk.48 It is likely that there are several genes that exhibit
such pleiotropic effects, which interact to contribute to
specific quantitative phenotypic traits or factors that
combine to form specific clusters (Supplementary
Table 1).
However, a defining feature of COPCs is that it is very
unlikely that a single genetic locus contains alleles that
are necessary or sufficient to produce the complex set
of signs and symptoms observed in COPCs. A substantial
percentage of the variability observedwith complex clin-
ical phenotypes are best explained by genetic polymor-
phisms that are relatively common (ie, >10%) in the
population, although the phenotypic penetrance of
these common variants is frequently not very high.89
Thus, the varied clinical phenotypes associated with
COPCs are likely the result of interactions between
many genetic variants of multiple genes that are re-
sponding to environmental exposures such as
anatomic-specific injuries, physical and psychological
stress, chemical exposures, infections, and a multitude
of negative and positive life events. As a result, interac-
tions among these distinct variants with a host of envi-
ronmental exposures produce a wide range of clinical
signs and symptoms so that not all patients show the
same broad spectrum of abnormalities in pain amplifica-
tion and affective vulnerability.
Because each individual patient with a COPCwill expe-
rience a unique set of environmental exposures, and
possess unique genetic antecedents to COPC vulnera-
bility and manifestation, the most efficient approach to
identify genetic markers for COPCs is to analyze the
interactive effects of polymorphic variants of multiple
functionally related genes. The complex interaction be-
tween these polymorphic variants will yield several
unique subtypes of patients who are susceptible to a va-
riety of COPCs. In addition, these multiple genetic path-
ways interact over time with environmental risk and
resilience factors to influence the mosaic of signs and
symptoms that define COPCs. A common and unifying
feature of these temporally dynamic conditions is the
expression of persistent pain as a primary symptom.
The identification of complex interactions between envi-
ronmental exposures and genetic susceptibility will
enable the development of newalgorithms andmethods
of diagnosing, classifying, and treating COPC patients.
Although genotyping is not yet a common methodused for diagnostic classification of people with chronic
pain, it seems likely that genetic testing or the assess-
ment of downstream biological processes such as protein
expression patterns will become an important compo-
nent of the AAPT diagnostic process in the future, as
additional evidence emerges regarding themolecular ar-
chitecture of chronic pain conditions, including COPCs.Classification and Diagnosis of COPCs
A challenge facing clinicians and researchers when
considering the concept of COPCs is that although
each of the diagnostic entities has its own case defini-
tion and classification criteria, there is still no consensus
on exactly how these conditions overlap or how best to
identify someone as a COPC ‘‘case.’’ As noted previously
(Epidemiology of COPCs) many individuals with 1 condi-
tion also tend to meet diagnostic criteria for other
conditions—but not everyone. This observation raises
the question of whether 1) each singular condition is a
primary problemwith some people exhibiting a second-
ary disorder (ie, COPC) that appears to overlap with the
primary condition(s), or 2) all of the conditions share a
common underlying mechanism (ie, COPC), and severity
varies along a continuumwith some individuals display-
ing only a singular manifestation whereas more severe
cases exhibit multiple conditions dictated by genetic
susceptibility and the nature of specific environmental
exposures. As noted previously, the degree to which
COPCs share common and unique risk vectors that re-
sults in clusters or groupings of COPCs is also an open
question.
Currently, the classification criteria for each condition
vary greatly in the rigor by which they were established,
with some including behavioral factors, some bio-
markers, and others self-reported symptoms. In addi-
tion, the evidence supporting the existing diagnostic
criteria varies notably across pain conditions. Table 1
shows the currently available options for classifying
each condition.
Although each condition appears to have some
unique anatomic pathophysiology, there is often shared
symptomatology (eg, widespread pain), epidemiology
(eg, higher female prevalence), and putative shared un-
derlying mechanisms (eg, pain amplification, psychoso-
cial, genetic) that suggest these conditions are related.
The challenge for clinicians has been how to classify in-
dividual patients with the goal of identifying the most
effective treatment for a COPC patient on the basis of
symptoms and mechanisms. All too often, treatment is
comprised solely of medications that target only pain,
to the exclusion of the many other signs and symptoms
that comprise the mosaic pattern of COPCs. To help
identify subgroups of patients that share common path-
ways of vulnerability, and who may respond to specific
treatments, there is a need for diagnostic and classifica-
tion schemes on the basis of biopsychosocial factors.22
The multidimensional AAPT framework represents a
step in this direction.33 To fully operationalize this
type of multidimensional classification, comprehensive
assessment is required. Pain assessment would include
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also include pain location, pain quality, pain distribu-
tion (eg, widespreadedness), and temporal patterns or
characteristics (see Fillingim et al, in this issue of The
Journal of Pain). As discussed elsewhere in this issue of
The Journal of Pain, by Edwards et al28 and Turk
et al,110 the comorbid symptoms that accompany many
of the COPCs must also be assessed, including: fatigue,
polysomatic illness burden, nonrestorative sleep, and
dyscognition (eg, poor memory, cognitive clarity, and
attention). Because chronic pain is heavily influenced
by affective factors, assessment of anxiety, dysphoria/
depression, anger, stress, trauma history, and personal-
ity should be included to identify subpopulations of
COPC patients who will respond to affect-specific phar-
macological and nonpharmacological therapies. Beliefs
and attitudes about pain also have strong relationships
to functional status and chronification.13,112 Such
cognitive factors can include catastrophizing, locus of
control, self-efficacy, expectancies, coping resources,
and resilience. Behavioral responses to COPCs include
functional status, fear avoidance, interference from
pain and disability, and finally interpersonal responses,
which often occur in social contexts can influence pain
(eg, evaluation of culture, family, work, and medical
support) as discussed by Turk et al110 in this issue of
The Journal of Pain.
Although assessing all of these domains is not practical
clinically, screening methods are needed that permit the
identification of patients requiring more intensive treat-
ments. Computer adaptive testing approaches also can
be implemented, which greatly reduce respondent
burden.103,104 In addition, more comprehensive
approaches can be useful in phenotyping and
mechanistic-based research. Work from the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) has helped to identify the primary do-
mains that should be used as outcome measures (eg, end
points) in the context of clinical trials of pain treatments,
which include: 1) pain intensity, 2) physical functioning,
3) emotional functioning, 4) overall improvement/well-
being, and (5) side effects.108,109 A similarly
multidimensional approach is important for classification
of chronic pain conditions. An even smaller subset may
be possible when the purpose of assessment is disease or
symptom monitoring over time. However, a broader set
of biopsychosocial variables, including genetic factors,
need to be assessed to determine the mechanistic factors
that are either unique or shared by COPCs.
Despite our ability to assess multiple facets relevant to
COPCs, treatment of COPCs and chronic painmore gener-
ally, remains challenging. Current interventions retain a
focus on sensory aspects of pain despite the knowledge
that chronic pain is heavily influenced by biopsychosocial
factors.7,56,73 Evidence-based approaches suggest that
combinations of traditional and centrally acting medica-
tion produce modest benefits for many COPCs16 and
that combiningmedicationswith nonpharmacological in-
terventions can produce even greater benefits in pain re-
lief and functional status for many of the COPCs. For
example, psychological interventions show significantbenefits in individuals with FM,125 IBS,61 chronic lower
back pain,51 and headache.27 However, clinical pain re-
ductions with these interventions may only help a subset
and overall can appear to be modest.3,124,125 Additional
nonmedical interventions, such as exercise, also can
benefit individuals with COPCs.14,100
Despite some positive evidence for combination ther-
apy for COPCs,16 clinical outcomes remain suboptimal
and additional research and stratification methods are
needed. This may be in part attributable to the failure
to appropriately incorporate COPCs into the design and
conduct of most clinical trials. Indeed, clinical trials for
pain treatments typically target a specific pain condition,
and the presence of other pain conditions is often an
exclusion criterion.67,94 Thus, individuals with COPCs
are significantly under-represented in clinical trials, re-
sulting in a dearth of information regarding safe and
effective therapies for patients with these common con-
ditions.
Several steps can be taken to address this situation.
First, clinical trials should incorporate rather than
exclude COPCs into their designs. The most basic
approach would be for a clinical trial of a treatment for
a specific COPC (eg, low back pain) to allow inclusion
of people with additional COPCs, collecting detailed in-
formation on the presence and severity of other condi-
tions. An alternative approach would be to conduct a
trial to determine the efficacy of a treatment for COPCs
rather than for specific individual pain conditions. This
would require an agreed upon case classification for
COPCs as well as systematic collection of data about
each of the pain conditions a patient endorses. If COPCs
are driven by common underlying mechanisms, treat-
ments designed to address those mechanisms should be
effective for COPCs broadly defined.
Regardless of how future trials account for COPCs,
another important step will be to collect more compre-
hensive biopsychosocial and molecular data, across mul-
tiple domains, to allow investigators to identify
subgroups that reflect potentially distinct pathophysio-
logic mechanisms (Fig 4). Broad-based information
regarding clinical features, pain amplification, and psy-
chosocial functioning can be subjected to sophisticated
statistical approaches (eg, cluster analysis, latent class
analysis) to permit identification of phenotypic profiles.
These phenotypic data can then be combined with ge-
netic and other biomarker data to characterize the bio-
logical mechanisms contributing to the empirically
defined subgroups. Stratified analysis can then be per-
formed to identify subgroups that are particularly
responsive (or nonresponsive) to treatment. Future
research will need to focus on which combinations of as-
sessed domains (eg, sensory, cognitive, affective, behav-
ioral) and procedures provide the most rational routes
into the subclassification and the identification of treat-
ment targets for specific strata or clusters of COPCs, with
the goal of providing meaningful pain relief, restoration
of function, and improved quality of life. Historically a
singular focus on reduction in anatomically specific clin-
ical pain has proven to be inadequate for meaningful
treatment of COPCs.
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1. Develop an empirically validated, evidence-based,
and mechanistically-driven case classification for
COPCs.
2. Design clinical trials that incorporate rather than
exclude COPCs to promote identification of safe
and effective therapies for patients with these con-
ditions.
3. Develop phenotyping assessment procedures that
can be readily operationalized that permit the sub-
grouping of patients with COPCs on the basis of
pathophysiological mechanisms. This could lead to
new nonanatomically based diagnostic taxonomies
as well as the identification of subgroups for whom
specific therapies are highly efficacious.
4. Conduct research on subgroups of COPCs to iden-
tify underlying molecular mechanisms and targetsfor intervention (pharmacological and nonpharma-
cological).
5. Examine interventions that focus on the ameliora-
tion of vulnerability factors and engagement of re-
silience factors in subgroups of COPCs.
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